These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36579915)

  • 21. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in Japanese patients with type 2 diabetes mellitus.
    Sarashina A; Ueki K; Sasaki T; Tanaka Y; Koiwai K; Sakamoto W; Woerle HJ; Salsali A; Broedl UC; Macha S
    Clin Ther; 2014 Nov; 36(11):1606-15. PubMed ID: 25199997
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment.
    Tayo B; Taylor L; Sahebkar F; Morrison G
    Clin Pharmacokinet; 2020 Jun; 59(6):747-755. PubMed ID: 31802404
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hydromorphone: pharmacology and clinical applications in cancer patients.
    Sarhill N; Walsh D; Nelson KA
    Support Care Cancer; 2001 Mar; 9(2):84-96. PubMed ID: 11305075
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Opioids for Cancer Pain and its Use under Particular Conditions: A Narrative Review].
    Vieira C; Brás M; Fragoso M
    Acta Med Port; 2019 May; 32(5):388-399. PubMed ID: 31166900
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients.
    Inoue S; Saito Y; Tsuneto S; Aruga E; Takahashi H; Uemori M
    Jpn J Clin Oncol; 2018 Jun; 48(6):542-547. PubMed ID: 29659913
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of Renal Impairment on Steady-State Plasma Concentrations of Rivastigmine: A Population Pharmacokinetic Analysis of Capsule and Patch Formulations in Patients with Alzheimer's Disease.
    Lefèvre G; Callegari F; Gsteiger S; Xiong Y
    Drugs Aging; 2016 Oct; 33(10):725-736. PubMed ID: 27681702
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate renal impairment.
    Venkatakrishnan K; Liu Y; Noe D; Mertz J; Bargfrede M; Marbury T; Farbakhsh K; Oliva C; Milton A
    Br J Clin Pharmacol; 2014 Jun; 77(6):986-97. PubMed ID: 24134181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic study of memantine in healthy and renally impaired subjects.
    Periclou A; Ventura D; Rao N; Abramowitz W
    Clin Pharmacol Ther; 2006 Jan; 79(1):134-43. PubMed ID: 16413248
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of pregabalin in subjects with various degrees of renal function.
    Randinitis EJ; Posvar EL; Alvey CW; Sedman AJ; Cook JA; Bockbrader HN
    J Clin Pharmacol; 2003 Mar; 43(3):277-83. PubMed ID: 12638396
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics and protein binding of eprosartan in healthy volunteers and in patients with varying degrees of renal impairment.
    Martin DE; Chapelsky MC; Ilson B; Tenero D; Boike SC; Zariffa N; Jorkasky DK
    J Clin Pharmacol; 1998 Feb; 38(2):129-37. PubMed ID: 9549643
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics, safety, and tolerability of maraviroc in HIV-negative subjects with impaired renal function.
    Vourvahis M; Fang J; Checchio T; Milton A; Weatherley B; McFadyen L; Heera J
    HIV Clin Trials; 2013; 14(3):99-109. PubMed ID: 23835512
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment.
    Rolfo C; de Vos-Geelen J; Isambert N; Molife LR; Schellens JHM; De Grève J; Dirix L; Grundtvig-Sørensen P; Jerusalem G; Leunen K; Mau-Sørensen M; Plummer R; Learoyd M; Bannister W; Fielding A; Ravaud A
    Clin Pharmacokinet; 2019 Sep; 58(9):1165-1174. PubMed ID: 30877569
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and safety of ebastine in healthy subjects and patients with renal impairment.
    Noveck RJ; Preston RA; Swan SK
    Clin Pharmacokinet; 2007; 46(6):525-34. PubMed ID: 17518511
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole.
    Mallikaarjun S; Shoaf SE; Boulton DW; Bramer SL
    Clin Pharmacokinet; 2008; 47(8):533-42. PubMed ID: 18611062
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics, safety and tolerance of voriconazole in renally impaired subjects: two prospective, multicentre, open-label, parallel-group volunteer studies.
    Abel S; Allan R; Gandelman K; Tomaszewski K; Webb DJ; Wood ND
    Clin Drug Investig; 2008; 28(7):409-20. PubMed ID: 18544001
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of zanamivir following intravenous administration to subjects with and without renal impairment.
    Weller S; Jones LS; Lou Y; Peppercorn A; Ng-Cashin J
    Antimicrob Agents Chemother; 2013 Jul; 57(7):2967-71. PubMed ID: 23587959
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies.
    Tomkinson H; Kemp J; Oliver S; Swaisland H; Taboada M; Morris T
    BMC Clin Pharmacol; 2011 Mar; 11():3. PubMed ID: 21414193
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function.
    Sharma S; Witteveen PO; Lolkema MP; Hess D; Gelderblom H; Hussain SA; Porro MG; Waldron E; Valera SZ; Mu S
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):87-95. PubMed ID: 25377157
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects.
    Hill HF; Coda BA; Tanaka A; Schaffer R
    Anesth Analg; 1991 Mar; 72(3):330-6. PubMed ID: 1704690
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Steady-state pharmacokinetics of extended-release hydromorphone (OROS hydromorphone): a randomized study in healthy volunteers.
    Moore KT; St-Fleur D; Marricco NC; Ariyawansa J; Pagé V; Natarajan J; Morelli G; Richarz U
    J Opioid Manag; 2010; 6(5):351-8. PubMed ID: 21046932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.